Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ariel Aviv"'
Autor:
Ehud Rozner, Ofir Koren, Yoav Turgeman, Elya Halfin, Moran Avraham Kelbert, Liza Lihtman, Ariel Aviv
Publikováno v:
Clinical Case Reports
Clinical Case Reports, Vol 9, Iss 4, Pp 2305-2309 (2021)
Clinical Case Reports, Vol 9, Iss 4, Pp 2305-2309 (2021)
Same clinical entity can have different biology and can behave differently. This must be kept in mind while making therapeutic decisions. Primary effusion lymphoma is a rare and devastating disease with high fatality. Chemotherapy provides limited be
Autor:
Orna Baron-Epel, Ilana Hellman, Vered Yahalom, Ariel Aviv, Tsofia Inbar, Meir Preis, Miri Zektser, Yakir Moshe, Lev Shvidel, Shai Yagenah, Maya Koren-Michowitz, Yossef Barshay, Tamar Tadmor, Najib Dally, Luiza Akria, Liza Barki-Harrington, Adir Shaulov, Merav Leiba, Dana Deshet
Publikováno v:
Palliative Medicine
Background: One of the main obstacles of providing home-based palliative care to transfusion-dependent hematology patients is the lack of home transfusions services. While healthcare professionals are concerned with safety and cost of home transfusio
Autor:
Ory Rouvio, Lev Shvidel, Michal Inbar, Andrei Braester, Uri Greenbaum, Mona Yuklea, Osnat Bairey, Neta Goldschmidt, Ariel Aviv, Najib Dally, Rosa Ruchlemer, Ilana Levy, Aaron Polliack, Tamar Tadmor, Adir Shaulov, Yair Herishanu, Riva Fineman
Publikováno v:
Leukemia Research. 82:24-28
Background Major advances in the treatment of patients with hairy cell leukemia (HCL) have been made following the introduction of purine analogues. The major significant short-term toxicity of cladribine therapy are neutropenia and neutropenic fever
Publikováno v:
Palliativesupportive care. 19(5)
ObjectiveHemato-oncologists are highly exposed to patients’ death and suffering during their daily work. The current exploratory and cross-sectional study examined death acceptance attitudes, in order to explore whether death acceptance attitudes a
Autor:
Rosa Ruchlemer, Angeles Medina Perez, Ariel Aviv, Alessandra Tedeschi, Sandra Bašić-Kinda, Sarit Assouline, Marta Morawska, Mihnea Zdrenghea, Maria Papaioannou, Gilad Itchaki, Viola Maria Popov, Odit Gutwein, Rosa Collado, Michael Gregor, Horia Bumbea, Inga Mandac, Livio Trentin, Neta Goldschmidt, Paolo Sportoletti, Adir Shaulov, Marta Coscia, Gian Matteo Rigolin, Anatoly Nemets, Francesca Romana Mauro, Róbert Szász, Nagib Dali, Fatima Miras, Massimo Gentile, Shimrit Ringelstein, Martin Simkovic, Martin Spacek, Uri Greenbaum, Aaron Polliack, Lydia Scarfò, Michael Doubek, Riva Fineman, Andrei Braester, Lev Shvidel, M.R. Nijziel, Irma Slavutsky, Tamar Tadmor, Eva Gimeno Vázquez, Yair Herishanu, Juan Marquet, Ozren Jakšić, Shai Levi, Ohad Benjamini, Javier Loscertales, Oana Stanca Ciocan, Paolo Ghia, Luciano Levato, Chava Perry, Maria Dimou, Anne De Meûter, Ewa Wasik-Szczepanek, Luca Laurenti, Osnat Bairey
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70727743ac43a6beabea873680dde4e
Autor:
Ariel Aviv, Lev Shvidel, Tamar Tadmor, Yair Herishanu, Naomi Rahimi-Levene, Andrea Braester, Aaron Polliack, Neta Goldschmidt, Erel Joffe, Riva Fineman, Uri Greenbaum, Rosa Ruchlemer, Osnat Bairey, Ariela Arad
Publikováno v:
European Journal of Haematology. 101:399-406
OBJECTIVE To evaluate disease characteristics and long-term outcomes in patients requiring second-line treatment following fludarabine, cyclophosphamide, and rituximab (FCR), for relapsed/refractory disease (R/R), or following discontinuation due to
Autor:
Riva Fineman, Aaron Polliack, Lev Shvidel, Neta Goldschmidt, Naomi Rahimi-Levene, Ariel Aviv, Uri Greenbaum, Rosa Ruchlemer, Andrei Braester, N. Ariela Arad, Osnat Bairey, Tamar Tadmor, Erel Joffe, Yair Herishanu
Publikováno v:
Hematological Oncology. 36:128-135
Decreased absolute lymphocyte counts (ALCs) following frontline therapy for chronic lymphocytic leukemia may be associated with disease control, even in patients without evidence of minimal residual disease. We studied the prognostic significance of
Autor:
Stefano Sacchi, Luigi Marcheselli, Luca Baldini, Aaron Polliack, Raffaella Marcheselli, Ariel Aviv, Massimo Federico, Sacchi Samantha Pozzi, Maria Christina Cox, Angela Ferrari, Tamar Tadmor, Giuseppe Pugliese, Paolo G. Gobbi, Alessia Bari
Publikováno v:
Hematological Oncology. 35:561-566
Several studies have demonstrated the prognostic value of neutrophil-lymphocyte ratio (NLR) in patients with solid tumors and non–Hodgkin lymphoma. In contrast, there is only sparse data on its prognostic role in patients with classical Hodgkin lym
Autor:
Andrei Braester, Lev Shvidel, Uri Greenbaum, Adir Shaulov, Mona Yuklea, Aaron Polliack, Rosa Ruchlemer, Ory Rouvio, Tamar Tadmor, Osnat Bairey, Yair Herishanu, Neta Goldschmidt, Michal Inbar, Dally Najib, Riva Fineman, Ariel Aviv
Publikováno v:
Anticancer research. 38(11)
Background/aim In this retrospective study, we summarized the national Israeli experience with hairy cell leukemia (HCL) in a large cohort of patients with a long follow-up. Patients and methods Demographic data, and relevant laboratory and clinical
Autor:
Andrei Braester, Tamar Tadmor, Osnat Bairey, Yair Herishanu, Aaron Polliack, Ariel Aviv, Itai Levi, Lev Shvidel, Naomi Rahimi-Levene, Rosa Ruchlemer, Mona Yuklea, Riva Fineman
Publikováno v:
Hematological oncology. 37(2)
Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL; however, this combination is toxic for older pa